Author | Edwin M. Posadas, MD, FACP | OncLive

Author | Edwin M. Posadas, MD, FACP


Dr. Posadas Discusses Cabozantinib in Prostate Cancer

June 11, 2014


Edwin M. Posadas, MD, FACP, medical director, Urologic Oncology Program, Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute, discusses a translational phase II study of cabozantinib in men with metastatic castration-resistant prostate cancer(mCRPC) with visceral metastases with characterization of circulating tumor cells and large oncosomes.